-
Je něco špatně v tomto záznamu ?
Pancreatic Neuroendocrine Microtumors (WHO 2022) Are Not Always Low-Grade Neoplasms: A Case with a Highly Increased Proliferation Rate
A. Chouchane, P. Kirchner, I. Marinoni, E. Sticová, T. Jirásek, A. Perren
Jazyk angličtina Země Spojené státy americké
Typ dokumentu kazuistiky, časopisecké články
Grantová podpora
188639
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
NLK
ProQuest Central
od 1997-04-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1997-03-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-04-01 do Před 1 rokem
- MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory slinivky břišní * patologie genetika MeSH
- neuroendokrinní nádory * patologie genetika MeSH
- proliferace buněk MeSH
- protoonkogenní proteiny genetika MeSH
- stupeň nádoru MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
Traditionally considered non-functional low proliferative benign neuroendocrine proliferations measuring less than 5 mm, pancreatic (neuro)endocrine microadenomas are now classified as pancreatic neuroendocrine microtumors in the 2022 WHO classification of endocrine and neuroendocrine tumors. This case report discussed the features of an incidentally identified 4.7-mm glucagon-expressing pancreatic neuroendocrine microtumor with MEN1 mutation only, chromosomally stable and an epigenetic alpha-like phenotype. The tumor was associated with an unexplained increased proliferation rate in Ki-67 of 15%. There was no associated DAXX/ATRX deficiency. The presented case challenges the conventional thought of a low proliferative disease of the so-called "pancreatic neuroendocrine microadenomas" and provides additional support to the 2022 WHO classification that also requires grading of these neoplasms. Despite exhibiting molecular features of less aggressive behavior, the case also underscores the biological complexity of pancreatic neuroendocrine microtumors. By recognizing the heterogenous spectrum of neuroendocrine neoplasms, the current case also contributes to ongoing discussions on how to optimize the clinical management of such tumors.
Department of Pathology Liberec Regional Hospital Liberec Czech Republic
Institute For Tissue Medicine and Pathology University of Bern Bern Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013775
- 003
- CZ-PrNML
- 005
- 20240905133345.0
- 007
- ta
- 008
- 240725s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12022-024-09802-7 $2 doi
- 035 __
- $a (PubMed)38403790
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Chouchane, Aziz $u Institute For Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
- 245 10
- $a Pancreatic Neuroendocrine Microtumors (WHO 2022) Are Not Always Low-Grade Neoplasms: A Case with a Highly Increased Proliferation Rate / $c A. Chouchane, P. Kirchner, I. Marinoni, E. Sticová, T. Jirásek, A. Perren
- 520 9_
- $a Traditionally considered non-functional low proliferative benign neuroendocrine proliferations measuring less than 5 mm, pancreatic (neuro)endocrine microadenomas are now classified as pancreatic neuroendocrine microtumors in the 2022 WHO classification of endocrine and neuroendocrine tumors. This case report discussed the features of an incidentally identified 4.7-mm glucagon-expressing pancreatic neuroendocrine microtumor with MEN1 mutation only, chromosomally stable and an epigenetic alpha-like phenotype. The tumor was associated with an unexplained increased proliferation rate in Ki-67 of 15%. There was no associated DAXX/ATRX deficiency. The presented case challenges the conventional thought of a low proliferative disease of the so-called "pancreatic neuroendocrine microadenomas" and provides additional support to the 2022 WHO classification that also requires grading of these neoplasms. Despite exhibiting molecular features of less aggressive behavior, the case also underscores the biological complexity of pancreatic neuroendocrine microtumors. By recognizing the heterogenous spectrum of neuroendocrine neoplasms, the current case also contributes to ongoing discussions on how to optimize the clinical management of such tumors.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory slinivky břišní $x patologie $x genetika $7 D010190
- 650 12
- $a neuroendokrinní nádory $x patologie $x genetika $7 D018358
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a protoonkogenní proteiny $x genetika $7 D011518
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kirchner, Philipp $u Institute For Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
- 700 1_
- $a Marinoni, Ilaria $u Institute For Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
- 700 1_
- $a Sticová, Eva $u Clinical and Transplant Pathology Centre, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Jirásek, Tomáš $u Department of Pathology, Liberec Regional Hospital, Liberec, Czech Republic
- 700 1_
- $a Perren, Aurel $u Institute For Tissue Medicine and Pathology, University of Bern, Bern, Switzerland. aurel.perren@unibe.ch
- 773 0_
- $w MED00001517 $t Endocrine pathology $x 1559-0097 $g Roč. 35, č. 2 (2024), s. 147-153
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38403790 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133339 $b ABA008
- 999 __
- $a ok $b bmc $g 2143530 $s 1225641
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 35 $c 2 $d 147-153 $e 20240226 $i 1559-0097 $m Endocrine pathology $n Endocr Pathol $x MED00001517
- GRA __
- $a 188639 $p Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- LZP __
- $a Pubmed-20240725
